Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience

Nivolumab is an effective and safe treatment in HCC. Nivolumab is an effective and safe treatment in HCC.

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 9; no. 4; pp. 2162 - 2167
Main Authors Al jarroudi, Ouissam, Chaabouni, Hamed, Ulusakarya, Ayhan, Almohamad, Wathek, Gumus, Yusuf, Goldschmidt, Emma, Afqir, Said, Morère, Jean‐francois
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.04.2021
John Wiley and Sons Inc
Wiley
Subjects
Case Report
Case Reports
clinical outcomes
FDA approval
Hepatitis
hepatocellular carcinoma
Liver cancer
Lymphocytes
Medical prognosis
Monoclonal antibodies
Neutrophils
nivolumab
Response rates
survival
Tumors
clinical outcomes
nivolumab
hepatocellular carcinoma
survival
Online AccessGet full text

Cover

More Information
Summary:Nivolumab is an effective and safe treatment in HCC. Nivolumab is an effective and safe treatment in HCC.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.3970